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with ST segment elevation myocardial infarction
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A b s t r a c t
Background: Acute hyperglycaemia in patients with acute coronary syndromes (ACS) is associated with increased cardiovas-
cular (CV) risk among both diabetic and non-diabetic patients although the mechanisms underlying this association are not 
clearly understood. Acute hyperglycaemia in patients with ACS may be associated with increased systemic inflammation. 
Leukocytes are the major cellular mediators of inflammation and their elevated count is associated with higher CV event rate 
in ACS patients. Thus, it is possible that there is a relationship between acute hyperglycaemia and high leukocyte count and 
concomitant presence of these two conditions may contribute to increased CV risk among patients with ST segment elevation 
myocardial infarction (STEMI).
Aim: To investigate the relationship between acute hyperglycaemia and high leukocyte count and to evaluate its association 
with outcomes in patients with STEMI.
Methods: Glucose level and leukocyte count on admission were measured in 246 patients with STEMI admitted in 2004– 
–2007 to the First Department of Cardiology and Hypertension at the University Hospital in Cracow who were treated with 
an early invasive management strategy. Patients were divided into two groups, with acute hyperglycaemia (glycaemia on 
admission ≥ 7.8 mmol/L) and with normoglycaemia (glycaemia on admission < 7.8 mmol/L). Leukocyte count was defined 
as high when it was greater than or equal to the median in the overall study group.
Results: Acute hyperglycaemia was noted in 136 (55.3%) patients. Median leukocyte count on admission in the overall 
study group was 10.8 × 103/mm3 (interquartile range: 8.5–13.0). Significantly higher in-hospital mortality (11.8% vs. 1.8%, 
p = 0.0029) and higher rates of cardiogenic shock (10.3% vs. 0.9%, p = 0.0022), Killip class > 1 heart failure (HF; 44.1% 
vs. 20.0%, p < 0.0001), atrial fibrillation (11.0% vs. 3.6%, p = 0.0308), ventricular fibrillation (5.9% vs. 0.9%, p = 0.0389), 
repeated percutaneous coronary angioplasty (5.2% vs. 0.0%, p = 0.0158), the primary endpoint defined as death and/or 
cardiogenic shock (16.9% vs. 1.8%, p = 0.0001), and the secondary endpoint defined as atrial fibrillation and/or second 
or third degree atrioventricular block and/or HF and/or stroke/transient ischaemic attack (53.7% vs. 23.6%, p < 0.0001) 
were noted in the acute hyperglycaemia group in comparison with the normoglycaemic group. Adverse events were asso-
ciated with high leukocyte count in all patients and in both diabetic and non-diabetic subgroups. Mean leukocyte count was 
higher in patients who died (13.3 ± 4.01 vs. 11.0 ± 3.56 [103/mm3], p = 0.0115; 14.2 ± 1.59 vs. 10.8 ± 3.18 [103/mm3], 
p = 0.0210; and 13.5 ± 4.79 vs. 11.1 ± 3.72 [103/mm3], p = 0.0363 in the overall study group, diabetics and non- 
-diabetics, respectively), in patients with cardiogenic shock (14.0 ± 4.56 vs. 11.0 ± 3.52 [103/mm3], p = 0.0019; and 
15.4 ± 4.93 vs. 11.0 ± 3.66 [103/mm3], p = 0.0007 in the overall study group and non-diabetics, respectively), and in patients 
with HF (12.1 ± 3.78 vs. 10.8 ± 3.51 [103/mm3], p = 0.0083; and 12.1 ± 3.39 vs. 10.3 ± 2.90 [103/mm3], p = 0.0159 in 
the overall study group and diabetics, respectively) as compared to patients without respective adverse events. Glucose level 
on admission correlated positively with the on-admission leukocyte count. This correlation was statistically significant in the 
overall study group (r = 0.25, p < 0.0001), in diabetics (r = 0.27, p = 0.021), and in non-diabetics (r = 0.35, p < 0.0001). 
Patients with both acute hyperglycaemia and the leukocyte count greater than or equal to the median in the overall study 
group had a higher in-hospital risk of death and/or cardiogenic shock (odds ratio 17.6, 95% CI 1.9–165.3, p = 0.0122). 
Conclusions: Acute hyperglycaemia is associated with worse in-hospital outcomes in patients with STEMI. More severe in-
flammation (defined as leukocyte count on admission) is noted in STEMI patients with adverse events. A significant positive 
correlation can be seen between glucose level and leukocyte count on admission, and concomitant presence of both acute 
hyperglycaemia and more severe inflammation in patients with STEMI was found to be an independent predictor of poor 
in-hospital outcomes. 
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INTRODUCTION
Increased glucose level and more severe inflammation are often 
observed in the acute phase of myocardial infarction (MI) [1]. 
Numerous studies indicate that high leukocyte count, a simple 
marker of inflammation, is associated with increased mortality, 
worse left ventricular function, and larger areas of myocardial 
necrosis in patients with MI [2–6]. By increasing coagulation, 
leukocytes may also promote the no-reflow phenomenon [7]. 
Epidemiological studies indicate that acute hyperglyca-
emia occurs in all subsets of acute coronary syndromes (ACS), 
including ST segment elevation MI (STEMI), non-STEMI, and 
unstable angina, regardless of a previous diagnosis of diabetes 
[8]. It was shown that the risk of adverse cardiovascular out-
comes is increased in patients with ACS and acute hypergly-
caemia, and this effect is seen both in established diabetics and 
patients without previous diagnosis of diabetes [9]. Increased 
levels of inflammation markers such as C-reactive protein and 
tumour necrosis factor alpha, increased activation of adhesive 
molecules, increased leukocyte number and their cytotoxic 
activity, and increased synthesis of free oxygen radicals are 
often observed in ACS patients with hyperglycaemia in the 
acute phase, leading to increased cardiomyocyte necrosis and 
impairment of the microcirculation [10–12]. 
Thus, it seems that there is a relationship between acute 
hyperglycaemia and increased leukocyte count in patients 
with MI, and concomitant presence of these two conditions 
may adversely affect outcomes in this patient group. However, 
only scarce data are available regarding these associations.
METHODS
The study included patients admitted due to STEMI in 
2004–2007 to the First Department of Cardiology and Hy-
pertension at the University Hospital in Cracow who were 
treated with an early invasive management strategy. Overall, 
246 patients gave their consent for participation and were 
included into the study. Glucose level and leukocyte count 
on admission were measured in all patients. We analysed 
demographic data, co ronary angiographic parameters, elec-
trocardiographic changes, and selected laboratory parameters 
including peak troponin I and creatine kinase level, lipid 
profile, glycaemia on admission, creatinine level, and esti-
mated glomerular filtration rate (eGFR). We also assessed the 
presence of cardiovascular risk factors, i.e. smoking, obesity 
(body mass index > 30 kg/m2), arterial hypertension (systolic 
blood pressure [SBP] ≥ 140 mm Hg and/or diastolic blood 
pressure [DBP] ≥ 90 mm Hg), hypercholesterolaemia (plasma 
total cholesterol ≥ 4.5 mg/dL or low-density lipoprotein cho-
lesterol > 2.5 mg/dL). Left ventricular ejection fraction was 
estimated using the Simpson method, the Teichholz method, 
or by visual inspection of two-dimensional images during tran-
sthoracic echocardio graphy (Sonos 5500, Hewlett-Packard). 
STEMI was defined as the presence of clinical symptoms of 
ischaemia with persistent ST segment elevation in at least two 
contiguous leads or acute left bundle branch block on the 
electrocardiogram (ECG) and an associated elevation of myo-
cardial necrosis markers [13]. Cardiogenic shock was defined 
as hypotension (SBP < 90 mm Hg) or a decrease in mean arte-
rial pressure by > 30 mm Hg and/or oliguria (< 0.5 mL/kg/h) 
not due to arrhythmia and with normal intravascular volume 
or when inotropic drugs and/or intraaortic balloon counter-
pulsation were necessary to maintain SBP > 90 mm Hg [14]. 
Heart failure (HF) during hospitalisation was categorised using 
the Killip classification [13]. Symptoms of HF were defined as 
Killip class > 1. Epicardial coronary flow after percutaneous 
coronary intervention (PCI) was evaluated using the Throm-
bolysis In Myocardial Infarction (TIMI) flow grade classification 
[13]. No-reflow phenomenon was diagnosed when less than 
TIMI 3 grade flow was seen in the culprit artery after coronary 
angioplasty. The diabetic group included patients with pre-
viously established diabetes and those in whom the diagnosis 
of diabetes was made during the index hospitalisation based 
on the results of an oral glucose tolerance test performed 
before discharge in all patients without previous diagnosis 
of diabetes (glucose level ≥ 11.1 mmol/L at 120 min). The 
remaining patients were considered non-diabetics.
The study population was divided into two groups, with acute 
hyperglycaemia (glycaemia on admission ≥ 7.8 mmol/L) and 
with normoglycaemia (glycaemia on admission < 7.8 mmol/L). 
Leukocyte count was defined as high when it was greater than 
or equal to the median in the overall study group.
In-hospital endpoints included death, ventricular fibril-
lation, atrial fibrillation (AF), second or third degree atrioven-
tricular (AV) block, bleeding events (gastrointestinal bleeding, 
haemorrhagic stroke confirmed by computed tomography), 
symptoms of HF, stroke or transient ischaemic attack (TIA), 
repeated PCI during the index hospitalisation, and urgent 
coronary artery bypass grafting, with the primary endpoint 
defined as in-hospital death and/or cardiogenic shock, and 
the secondary endpoint defined as AF and/or second or third 
degree AV block and/or HF and/or stroke/TIA.
The study protocol was approved by the Bioethics Com-
mittee at the Jagiellonian University (KBET/47/B/2010).
Statistical analysis
Data were summarised using descriptive statistics, including 
median values and interquartile ranges or mean values and 
standard deviations for continuous variables, and numbers 
and percentages for categorical variables. Unpaired samples 
were compared using the Student t test for unpaired sam-
ples, and the nonparametric Mann-Whitney U test was used 
if baseline assumptions were not met (normal distribution, 
homogeneity of variance). Distribution normality was tested 
using the Shapiro-Wilk test, and homogeneity of variance 
between groups was tested using the Levene test. Paired 
samples were compared using the Student t test for paired 
samples, and the Wilcoxon test for paired samples was used 
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if baseline assumptions were not met (normality of variance). 
Categorical variables were compared using the Pearson χ2 test. 
Logistic regression model was used to identify factors affecting 
endpoint occurrence. Odds ratios (OR) with 95% confidence 
intervals (CI) were calculated for significant predictors. Rela-
tionships between continuous variables were evaluated by the 
Pearson correlation coefficient. In all analyses, p < 0.05 was 
considered statistically significant. All calculations and analyses 
were performed using the Statistica PL software, version 8.0.
RESULTS
The study included 246 patients admitted due to STEMI in 
2004–2007 to the First Department of Cardiology and Hy-
pertension at the University Hospital in Cracow who were 
treated with an early invasive management strategy. Median 
age in the overall study group was 64.5 years (interquartile 
range 55–72). The study group included 80 (32.5%) women. 
Forty-six (18.7%) patients were obese, 179 (72.8%) were hy-
pertensive, 118 (48.0%) had dyslipidaemia, and 107 (43.5%) 
were smokers. Diabetes was diagnosed in 75 (30.5%) pa-
tients. On admission, median glucose level was 8.0 mmol/L 
(interquartile range 6.8–10.8), and median leukocyte count 
was 10.8 × 103/mm3 (interquartile range 8.5–13.0).
Of the study population, 136 (55.3%) patients were in 
the acute hyperglycaemia group, and 110 (44.7%) patients 
had normoglycaemia. Patients with acute hyperglycaemia 
more often had diabetes (41.9% vs. 16.4%, p < 0.0001) and 
3-vessel disease (22.8% vs. 12.7%, p = 0.0423) compared 
to the normoglycaemic group. They were also characterised 
by lower left ventricular ejection fraction (47.5% vs. 50.0%, 
p = 0.0022), higher leukocyte count (11.3 vs. 9.9 × 103/mm3, 
p = 0.0134), higher peak troponin I level (9.9 vs. 5.1 ng/mL, 
p = 0.0323), and lower eGFR (68 vs. 78 mL/min/1.73 m2, 
p = 0.0006). Median glucose level was 10.2 mmol/L (inter-
quartile range 8.8–13.5) in the acute hyperglycaemia group 
and 6.7 mmol/L (interquartile range 6.1–7.3) in the normogly-
caemic group (p < 0.0001). Detailed demographic, clinical, 
and biochemical data are shown in Table 1.
Significantly higher in-hospital mortality (p = 0.0029) 
was noted in the acute hyperglycaemia group in comparison 
with the normoglycaemic group, as were the rates of Killip 
class > 1 HF (p < 0.0001), cardiogenic shock (p = 0.0022), 
ventricular fibrillation (p = 0.0389), the need for repeated 
PCI during the index hospitalisation (p = 0.0158), and both 
combined endpoints, i.e. death and/or cardiogenic shock 
(p = 0.0001), and AF and/or second or third degree AV block 
and/or HF and/or stroke/TIA (p < 0.0001). Detailed data on 
adverse events are shown in Table 2.
Leukocyte count on admission was higher in patients with 
adverse events compared to those with no adverse events. This 
effect was seen in the overall study group and in both diabetic 
and non-diabetic subgroups. Mean leukocyte count was higher 
Table 1. Demographic and clinical data and biochemical parameters
Normoglycaemia (glucose on  
admission < 7.8 mmol/L; n = 110)
Acute hyperglycaemia (glucose on 
admission ≥ 7.8 mmol/L; n = 136)
P
Age [years] 59 (53–70) 68 (57.5–74) 0.0020
Female gender 31 (28.2%) 49 (36.0%) 0.1914
Hypertension 77 (70.0%) 102 (75.0%) 0.3811
Diabetes 18 (16.4%) 57 (41.9%) < 0.0001
Dyslipidaemia 58 (52.7%) 60 (44.1%) 0.1790
Smoking 61 (55.5%) 46 (33.8%) 0.0007
Obesity 18 (16.4%) 28 (20.6%) 0.3982
Anterior infarction 40 (36.4%) 57 (42.2%) 0.3510
Three-vessel disease 14 (12.7%) 31 (22.8%) 0.0423
Previous myocardial infarction 15 (13.8%) 25 (18.4%) 0.3308
Ejection fraction [%] 50 (45–58) 47.5 (40–55) 0.0022
WBC [× 103/mm3] 9.9 (7.9–12.6) 11.3 (9.4–13.2) 0.0134
BMI [kg/m2] 26.15 (24–29) 28 (25–30) 0.0098
Peak troponin I [ng/mL] 5.1 (2.45–18.62) 9.9 (3.39–30) 0.0323
Peak CK [U/L] 966 (449–1981) 1376.5 (628–3736) 0.1836
Peak CK-MB [U/L] 116.5 (57.5–279) 191 (81–335) 0.1857
GFR [mL/min/1.73 m2] 78 (64–92) 68 (54–82) 0.0006
Glucose on admission [mmol/L] 6.7 (6.1–7.3) 10.2 (8.8–13.5) < 0.0001
BMI — body mass index; CK — creatine kinase; CK-MB — creatine kinase MB; GFR — glomerular filtration rate; WBC — white blood cell count
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in patients who died, in patients with cardiogenic shock, and 
in patients with HF as compared to patients without respective 
adverse events. Complete data are shown in Table 3.
Our analysis showed that glucose level on admission cor-
related positively with the on-admission leukocyte count. This 
correlation was statistically significant in the overall study group 
(r = 0.25, p < 0.0001), in diabetics (r = 0.27, p = 0.021), and 
in non-diabetics (r = 0.35, p < 0.0001) (Fig. 1).
A logistic regression model that included other risk fac-
tors (age, smoking, diabetes, hypertension, 3-vessel disease, 
Table 2. Adverse events during hospitalisation
Normoglycaemia  
(glucose on admission  
< 7.8 mmol/L; n = 110)
Acute hyperglycaemia  
(glucose on admission  
≥ 7.8 mmol/L; n = 136)
P
Death 2 (1.8%) 16 (11.8%) 0.0029
HF 22 (20.0%) 60 (44.1%) 0.0001
Cardiogenic shock 1 (0.9%) 14 (10.3%) 0.0022
2nd or 3rd degree AV block 4 (3.6%) 12 (8.8%) 0.1009
Atrial fibrillation 4 (3.6%) 15 (11.0%) 0.0308
Ventricular fibrillation 1 (0.9%) 8 (5.9%) 0.0389
Bleeding 1 (0.9%) 7 (5.2%) 0.0624
Repeated PCI 0 (0.0%) 7 (5.2%) 0.0158
Urgent CABG 4 (3.6%) 6 (4.4%) 0.7595
No-reflow 1 (0.9%) 5 (3.7%) 0.1618
Stroke/TIA 0 (0.0%) 1 (0.7%) 0.3675
Death and/or cardiogenic shock 2 (1.8%) 23 (16.9%) 0.0001
Atrial fibrillation and/or 2nd or 3rd degree  
AV block and/or HF and/or stroke/TIA
26 (23.6%) 73 (53.7%) < 0.0001
AV — atrioventricular; CABG — coronary artery bypass grafting; HF — heart failure; PCI — percutaneous coronary intervention; TIA — transient 
ischaemic attack
Table 3. Adverse events in relation to mean leukocyte count
Adverse event occurrence Mean leukocyte count [× 103/mm3] P
All patients Death Yes, n = 17 (6.9%)
No, n = 229 (93.1%)
13.3 ± 4.01
11.0 ± 3.56
0.0115
Heart failure Yes, n = 81 (32.9%)
No, n=165 (67.1%)
12.1 ± 3.78
10.8 ± 3.51
0.0083
Cardiogenic shock Yes, n = 15 (6.1%)
No, n = 231 (93.9%)
14.0 ± 4.56
11.0 ± 3.52
0.0019
Diabetics Death Yes, n = 5 (6.7%)
No, n = 70 (92.3%)
14.2 ± 1.59
10.8 ± 3.18
0.0210
Heart failure Yes, n = 31 (41.4%)
No, n = 44 (58.6%)
12.1 ± 3.39
10.3 ± 2.90
0.0159
Cardiogenic shock Yes, n = 6 (8.0%)
No, n = 69 (92.0%)
12.1 ± 3.55
11.0 ± 3.19
0.4242
Non-dia-
betics
Death Yes, n = 12 (7.0%)
No, n = 159 (93.0%)
13.5 ± 4.79
11.1 ± 3.72
0.0363
Heart failure Yes, n = 50 (29.2%)
No, n = 121 (70.8%)
12.1 ± 4.05
11.0 ± 3.70
0.0873
Cardiogenic shock Yes, n = 9 (5.3%)
No, n = 162 (94.7%)
15.4 ± 4.93
11.0 ± 3.66
0.0007
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Figure 1. Correlations between glucose level and leukocyte count on admission
Table 4. In-hospital risk of death and/or cardiogenic shock*
Odds ratio 95% CI P
Normoglycaemia and low leukocyte count 1 Reference –
Normoglycaemia and elevated leukocyte count 2.2 0.11–44.73 0.6145
Acute hyperglycaemia and low leukocyte count 4.2 0.42–41.66 0.2230
Acute hyperglycaemia and elevated leukocyte count 17.6 1.88–165.26 0.0122
*Logistic regression model included age, smoking, diabetes, hypertension, 3-vessel disease, TIMI 0 flow in the culprit artery before percutaneous 
coronary intervention, and anterior infarction; CI — confidence interval
TIMI 0 flow in the culprit artery before PCI, and anterior 
infarction) showed that acute hyperglycaemia combined with 
elevated leukocyte count (greater than or equal to the median 
in the overall study group) was an independent predictor of 
in-hospital death and/or cardiogenic shock (OR 17.6; 95% CI 
1.88–165.26, p = 0.0122) (Table 4).
DISCUSSION
Mechanisms of hyperglycaemia in patients with MI have not 
been clearly elucidated. Acute hyperglycaemia is usually con-
sidered a systemic response to stress, and this stress response 
in ACS is directed at short-term optimisation of cardiovascular 
system function. Another potential mechanism of acute hyper-
glycaemia may be previously undiagnosed diabetes or glucose 
metabolism disturbances. These disturbances may be mild and 
compensated chronically but manifest with acute disease and 
related hormonal imbalances. Thus, glycaemia on admission 
may be a marker of not only acute stress but also current and 
previous metabolic status. In addition, adverse effects of hy-
perglycaemia on outcomes in patients with ACS might be in 
part mediated by exacerbation of inflammatory processes [15]. 
Despite numerous published studies on acute hypergly-
caemia, there is no uniformly accepted blood glucose level that 
would define this condition. In various studies, hyperglycaemia 
was defined as blood glucose level on admission of 6.7– 
–11.1 mmol/L (120–200 mg/dL) or initial fasting glucose level of 
6.1–8.0 mmol/L (110–144 mg/dL) [15]. Acute hyperglycaemia 
has also not been clearly defined in the current guidelines. In the 
Polish Diabetes Society (Polskie Towarzystwo Diabetologiczne, 
PTD) guidelines on glucose lowering treatment in patients with 
ACS, relative hyperglycaemia necessitating intervention was 
defined as blood glucose level above 140 mg/dL (7.8 mmol/L) 
in subjects with previously established diabetes and above 
180 mg/dL (10.0 mmol/L) in subjects without previous diagnosis 
of diabetes [16]. In American guidelines on the management of 
critically ill patients published in 2011, hyperglycaemia requir-
ing glucose lowering treatment was defined as blood glucose 
level greater than or equal to 180 mg/dL (10.0 mmol/L) but 
this definition applied only to diabetic patients [17]. In contrast, 
cutoff glucose level defining hyperglycaemia in non-diabetics 
was not clearly defined in these guidelines [17]. In our study, 
acute hyperglycaemia was defined as blood glucose level on 
admission greater than or equal to 7.8 mmol/L (140 mg/dL), 
similarly to most other studies on this subject [15, 18, 19]. 
Previously, it was shown that acute hyperglycaemia in 
patients with ACS was associated with an increased risk of 
both in-hospital and long-term adverse outcomes regardless of 
previous diagnosis of diabetes [20–22]. Our findings indicate 
that hyperglycaemia in the acute phase of ACS results in an 
increased rate of in-hospital adverse cardiovascular events. Pa-
tients with acute hyperglycaemia had more risk indicators 
at baseline compared to patients with normoglycaemia, i.e. 
they were older and had lower left ventricular ejection frac-
tion, higher peak troponin I, and lower eGFR. In addition, 
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significantly higher in-hospital mortality and higher rates of 
HF, cardiogenic shock, AF, ventricular fibrillation, and the 
need for repeated PCI during the index hospitalisation were 
noted in the acute hyperglycaemia group in comparison with 
the normoglycaemic group. Both combined endpoints, i.e. 
death and/or cardiogenic shock, and AF and/or second or 
third degree AV block and/or HF and/or stroke/TIA, were also 
more common among patients with acute hyperglycaemia.
Numerous studies showed that increased inflammation 
(manifested, e.g., with elevated leukocyte count) in patients 
with MI is associated with worse outcomes [2–7]. In our study, 
leukocyte count on admission was higher in patients with 
adverse cardiovascular events compared to those without 
adverse events. This effect was seen in the overall study group, 
in diabetics, and in non-diabetics.
We also observed that patients with acute hypergly-
caemia showed higher leukocyte count on admission, and 
a positive correlation between glucose level and leukocyte 
count on admission was found both in the overall study 
group and in diabetic and non-diabetic subgroups. This is 
particularly important as some data indicate that increased 
levels of inflammatory markers such as C-reactive protein and 
tumour necrosis factor alpha, increased activation of adhesive 
molecules, increased synthesis of free oxygen radicals, and 
increased leukocyte number and their cytotoxic activity may 
in part result from hyperglycaemia itself [10–12].
It seems that there acute hyperglycaemia and elevated 
leukocyte count are closely related to each other, and STEMI 
patients with both acute hyperglycaemia and elevated leu-
kocyte count may be at a particularly high risk of adverse 
outcomes. A logistic regression model employed in our study 
confirmed that concomitant presence of both acute hyper-
glycaemia and elevated leukocyte count was an independent 
predictor of in-hospital death and/or cardiogenic shock.
Our findings indicate that acute hyperglycaemia may 
be not only a marker but also a mediator of worse outcomes 
in this patient group, and increased inflammation seen in 
patients with elevated blood glucose level in the acute phase 
of MI may be at least partially responsible for the observed 
association between acute hyperglycaemia in ACS and worse 
outcomes in these patients.
CONCLUSIONS
Acute hyperglycaemia is associated with worse in-hospital 
outcomes in patients with STEMI. More severe inflammation 
(defined as leukocyte count on admission) is noted in STEMI pa-
tients with adverse events. A significant positive correlation can 
be seen between glucose level and leukocyte count on admis-
sion, and concomitant presence of both acute hyperglycaemia 
and more severe inflammation in patients with STEMI was found 
to be an independent predictor of poor in-hospital outcomes.
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Ostra hiperglikemia i stan zapalny u pacjentów  
z zawałem serca z uniesieniem odcinka ST
Michał Terlecki, Agnieszka Bednarek, Kalina Kawecka-Jaszcz, Danuta Czarnecka, Leszek Bryniarski
I Klinika Kardiologii i Nadciśnienia Tętniczego, Collegium Medicum, Uniwersytet Jagielloński, Kraków
S t r e s z c z e n i e
Wstęp: Występująca u pacjentów z ostrym zespołem wieńcowym (OZW) ostra hiperglikemia wiąże się ze zwiększonym 
ryzykiem sercowo-naczyniowym zarówno wśród osób z cukrzycą, jak i bez cukrzycy. Mechanizmy odpowiedzialne za gorsze 
rokowanie tej grupy chorych nie są jednak dobrze poznane. Ostra hiperglikemia u pacjentów z OZW może się wiązać z bar-
dziej nasilonym stanem zapalnym. Leukocyty są głównymi komórkowymi wskaźnikami stanu zapalnego, a ich podwyższony 
poziom jest związany z częstszym występowaniem niekorzystnych zdarzeń sercowo-naczyniowych u pacjentów z OZW. Dane 
te wskazują, że może istnieć związek między ostrą hiperglikemią a podwyższonym stężeniem leukocytów, a współwystępo-
wanie obu tych stanów może korelować ze zwiększonym ryzykiem sercowo-naczyniowym u pacjentów z ostrym zawałem 
serca z uniesieniem odcinka ST (STEMI).
Cel: Celem pracy była ocena zależności między ostrą hiperglikemią a nasileniem stanu zapalnego (ocenianego poprzez poziom 
leukocytozy) i wpływu tych stanów na rokowanie u pacjentów ze STEMI.
Metody: U 246 osób hospitalizowanych w latach 2004–2006 w I Klinice Kardiologii i Nadciśnienia Tętniczego Szpitala Uni-
wersyteckiego w Krakowie z powodu STEMI, zakwalifikowanych do pilnej diagnostyki inwazyjnej choroby niedokrwiennej 
serca oznaczano stężenie glukozy i leukocytów przy przyjęciu. Pacjentów podzielono na grupę z ostrą hiperglikemią (stężenie 
glukozy przy przyjęciu ≥ 7,8 mmol/l) oraz grupę z normoglikemią (stężenie glukozy przy przyjęciu < 7,8 mmol/l). Stężenie 
leukocytów większe lub równe medianie uznano za podwyższone.
Wyniki: Ostrą hiperglikemię stwierdzono u 136 (55.3%) pacjentów. Mediana stężenia leukocytów wszystkich badanych 
chorych wynosiła 10,8 tys./m3 (przedział międzykwartylowy: 8,5–13,0). W grupie z ostrą hiperglikemią w porównaniu z gru-
pą z normoglikemią śmiertelność w czasie hospitalizacji była istotnie wyższa (11,8% vs. 1,8%; p = 0,0029). U tych chorych 
zaobserwowano również istotnie częściej niewydolność serca (HF) z klasą Killipa > 1 (44,1% vs. 20,0%; p = 0,0001), wstrząs 
kardiogenny (10,3% vs. 0,0%; p = 0,0022), migotanie przedsionków (11,0% vs. 3,6%; p = 0,0308), migotanie komór (5,9% 
vs. 0,9%; p = 0,0389) oraz częściej istniała konieczność wykonania ponownej przezskórnej interwencji wieńcowej podczas 
hospitalizacji (5,2% vs. 0,0%; p = 0,0158). U chorych z ostrą hiperglikemią częściej obserwowano występowanie złożonych 
punktów końcowych, tj.: zgonu i/lub wstrząsu kardiogennego (16,9% vs. 1,8%; p = 0,0001) i migotania przedsionków i/lub 
bloku przedsionkowo-komorowego II lub III stopnia i/lub HF i/lub udaru mózgu/przejściowego ataku niedokrwiennego (53,7% 
vs. 23,6%; p < 0,0001). Stężenie leukocytów przy przyjęciu było wyższe u chorych, u których wystąpiły niekorzystne zda-
rzenia, w porównaniu z pacjentami, u których nie zaobserwowano powikłań. Chorzy, którzy zmarli w czasie hospitalizacji, 
mieli istotnie wyższe stężenie leukocytów przy przyjęciu (średnia ± odchylenie standardowe) w porównaniu z pacjentami, 
którzy przeżyli (13,3 ± 4,01 vs. 11,0 ± 3,56 tys./mm3; p = 0,0115; 14,2 ± 1,59 vs. 10,8 ± 3,18 tys./mm3; p = 0,0210; 
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13,5 ± 4,79 vs. 11,1 ± 3,72 tys./mm3; p = 0,0363, odpowiednio dla wszystkich badanych chorych, podgrupy z cukrzycą 
i bez cukrzycy). U chorych ze wstrząsem kardiogennym w czasie hospitalizacji także stwierdzono istotnie wyższe średnie 
stężenie glukozy przy przyjęciu (14,0 ± 4,56 vs. 11,0 ± 3,52 tys./mm3; p = 0,0019; 15,4 ± 4,93 vs. 11,0 ± 3,66 tys./mm3; 
p = 0,0007, odpowiednio dla wszystkich badanych chorych i podgrupy bez cukrzycy). Podobną zależność dla średniego stężenia 
glukozy stwierdzono u osób z HF (12,1 ± 3,78 vs. 10,8 ± 3,51 tys./mm3; p = 0,0083; 12,1 ± 3,39 vs. 10,3 ± 2,90 tys./mm3; 
p = 0,0159, odpowiednio dla wszystkich badanych chorych i podgrupy z cukrzycą). Stwierdzono dodatnią korelację między 
stężeniem glukozy i leukocytów przy przyjęciu u wszystkich badanych chorych (r = 0,25; p < 0,0001), a także w podgrupie 
z cukrzycą (r = 0,27; p = 0,0210) i bez cukrzycy (r = 0,35; p < 0,0001). Współwystępowanie ostrej hiperglikemii i stężenia 
leukocytów większego lub równego medianie wiązało się z wyższym ryzykiem zgonu i/lub wstrząsu kardiogennego w obser-
wacji wewnątrzszpitalnej (OR = 17,6; 95% CI 1,9–165,3; p = 0,0122).
Wnioski: Występowanie ostrej hiperglikemii w STEMI wiąże się z gorszym rokowaniem wewnątrzszpitalnym. Stan zapalny 
(oceniany wartością leukocytozy przy przyjęciu) jest bardziej nasilony u chorych ze STEMI, u których występują niekorzystne 
zdarzenia. Istnieje dodatnia korelacja między stężeniem glukozy i leukocytów przy przyjęciu, a współwystępowanie ostrej 
hiperglikemii i nasilonego procesu zapalnego jest niezależnym czynnikiem gorszego rokowania wewnątrzszpitalnego u pa-
cjentów ze STEMI.
Słowa kluczowe: ostra hiperglikemia, leukocyty, stan zapalny, zawał serca z uniesieniem odcinka ST
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